| Sign In to gain access to subscriptions and/or personal tools. |
Review: Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome2200 North Commerce Parkway, Suite 300 Weston, Florida 33326 — 3258 USA, mmcgovern{at}kospharm.com This paper will focus on the use of nicotinic acid as a therapeutic option for cardiovascular risk reduction in patients with abnormal glucose metabolism and `atherogenic dyslipidaemia'. This is characterised by low levels of HDL-C, high triglycerides, and preponderance of small, dense LDL particles. Whilst nicotinic acid may increase plasma glucose in some patients, more recent studies show that the effect of nicotinic acid on glycaemic control is minimal in the majority of patients, and that nicotinic acid decreases the risk of cardiac events in patients with elevated fasting glucose, diabetes, or metabolic syndrome.
Key Words: dyslipidaemia IFG diabetes metabolic syndrome nicotinic acid.
The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 2,
78-85 (2004) |
||||